Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E10A plus pembrolizumab versus pembrolizumab in PD-L1-high recurrent/metastatic head and neck squamous cell carcinoma
CTR20233377Phase 2Active
- Sponsor
- Guangzhou Doublle Bioproduct Co., Ltd.
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Recombinant human endostatin adenovirus, pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Guangzhou Doublle Bioproduct Co., Ltd.. Started May 2024; status: active.
02
Drugs
Recombinant human endostatin adenoviruspembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20233377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233377.